Biophysical characterization and immunization studies of dominant negative inhibitor (DNI), a candidate anthrax toxin subunit vaccine

被引:7
作者
Iyer, Vidyashankara [1 ,2 ]
Hu, Lei [1 ]
Schante, Carole E. [1 ]
Vance, David [3 ]
Chadwick, Chrystal [3 ]
Jain, Nishant Kumar [1 ]
Brey, Robert N. [4 ]
Joshi, Sangeeta B. [1 ]
Volkin, David B. [1 ,2 ]
Andra, Kiran K. [5 ]
Bann, James G. [5 ]
Mantis, Nicholas J. [3 ]
Middaugh, C. Russell [1 ,2 ]
机构
[1] Univ Kansas, Dept Pharmaceut Chem, Macromol & Vaccine Stabilizat Ctr, Lawrence, KS 66045 USA
[2] Univ Kansas, Bioengn Grad Program, Lawrence, KS 66045 USA
[3] Wadsworth Ctr, Div Infect Dis, Albany, NY USA
[4] Soligenix, Princeton, NJ USA
[5] Wichita State Univ, Dept Chem, Wichita, KS 67208 USA
关键词
dominant-negative inhibitor; vaccine; aluminum hydroxide; immunogenicity; accelerated stability; biophysical characterization; RECOMBINANT PROTECTIVE ANTIGEN; RECEPTOR; DEAMIDATION; STABILITY; RECOMMENDATIONS; IMMUNOGENICITY; TRANSLOCATION; FORMULATIONS; DELIVERY; THERAPY;
D O I
10.4161/hv.25852
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Dominant negative inhibitor (DNI) is a translocation-deficient homolog of recombinant protective antigen of Bacillus anthracis that is a candidate for a next generation anthrax vaccine. This study demonstrates that the biophysical characteristics of the DNI protein stored in lyophilized form at 4 degrees C for 8 y were similar to recombinant protective antigen (rPA). To provide information on the accelerated stability of DNI, samples in the lyophilized form were subjected to thermal stress (40 and 70 degrees C for up to 4 weeks) and thoroughly evaluated using various biophysical and chemical characterization techniques. Results demonstrate preserved structural stability of the DNI protein under extreme conditions, suggesting long-term stability can be achieved for a vaccine that employs DNI, as desired for a biodefense countermeasure. Furthermore, the biological activity of the stressed DNI bound to the adjuvant Alhydrogel (R) was evaluated in mice and it was found that the immunogenicity of DNI was not affected by thermal stress.
引用
收藏
页码:2362 / 2370
页数:9
相关论文
共 23 条
[1]   Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines [J].
Aulinger, BA ;
Roehrl, MH ;
Mekalanos, JJ ;
Collier, RJ ;
Wang, JY .
INFECTION AND IMMUNITY, 2005, 73 (06) :3408-3414
[2]   Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants [J].
Berthold, I ;
Pombo, ML ;
Wagner, L ;
Arciniega, JL .
VACCINE, 2005, 23 (16) :1993-1999
[3]   Reduction of Immunogenicity of Anthrax Vaccines Subjected to Thermal Stress, as Measured by a Toxin Neutralization Assay [J].
Castelan-Vega, Juan ;
Corvette, Laura ;
Sirota, Lev ;
Arciniega, Juan .
CLINICAL AND VACCINE IMMUNOLOGY, 2011, 18 (02) :349-351
[4]   Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine [J].
D'Souza, Ajit Joseph M. ;
Mar, Kevin D. ;
Huang, Joanne ;
Majumdar, Sumit ;
Ford, Brandi M. ;
Dyas, Beverly ;
Ulrich, Robert G. ;
Sullivan, Vincent J. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2013, 102 (02) :454-461
[5]   Anthrax [J].
Dixon, TC ;
Meselson, M ;
Guillemin, J ;
Hanna, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :815-826
[6]   Vaccines for preventing anthrax [J].
Donegan, Sarah ;
Bellamy, Richard ;
Gamble, Carrol L. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02)
[7]   Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue [J].
Hu, Lei ;
Joshi, Sangeeta B. ;
Andra, Kiran K. ;
Thakkar, Santosh V. ;
Volkin, David B. ;
Bann, James G. ;
Middaugh, C. Russell .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (11) :4118-4128
[8]   Investigation of Protein Conformational Stability Employing a Multimodal Spectrometer [J].
Hu, Lei ;
Olsen, Christopher ;
Maddux, Nathan ;
Joshi, Sangeeta B. ;
Volkin, David B. ;
Middaugh, C. Russell .
ANALYTICAL CHEMISTRY, 2011, 83 (24) :9399-9405
[9]   Anthrax as a biological weapon, 2002 - Updated recommendations for management [J].
Inglesby, TV ;
O'Toole, T ;
Henderson, DA ;
Bartlett, JG ;
Ascher, MS ;
Eitzen, E ;
Friedlander, AM ;
Gerberding, J ;
Hauer, J ;
Hughes, J ;
McDade, J ;
Osterholm, MT ;
Parker, G ;
Perl, TM ;
Russell, PK ;
Tonat, K .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (17) :2236-2252
[10]   Anthrax vaccine powder formulations for nasal mucosal delivery [J].
Jiang, G ;
Joshi, SB ;
Peek, LJ ;
Brandau, DT ;
Huang, J ;
Ferriter, MS ;
Woodley, WD ;
Ford, BM ;
Mar, KD ;
Mikszta, JA ;
Hwang, CR ;
Ulrich, R ;
Harvey, NG ;
Middaugh, CR ;
Sullivan, VJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 95 (01) :80-96